why choose us

Course: Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

CME Credits: 1.00

Released: 2021-11-23

Following massive global initiatives, the US Food and Drug Administration approved several SARS-CoV-2 vaccines, including the BNT162b2 (Pfizer-BioNTech) mRNA vaccine. While manifestations of COVID-19 are heterogeneous, patients with solid tumors undergoing active therapy are at considerable risk for worse outcomes., Among these patients, humoral response to SARS-CoV-2 vaccines has been reported in approximately 90%. Although high, this proportion is considerably lower than the 99% to 100% found in control groups. Among patients who are treated with chemotherapy, further reduced humoral responses have been described.


Educational Objective
To identify the key insights or developments described in this article


View Full Course